Your browser doesn't support javascript.
loading
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01).
Rasmussen, Louise Skau; Winther, Stine B; Chen, Inna M; Weber, Britta; Ventzel, Lise; Liposits, Gabor; Johansen, Julia Sidenius; Detlefsen, Sönke; Egendal, Ida; Shim, Susy; Christensen, Signe; Pfeiffer, Per; Ladekarl, Morten.
Afiliação
  • Rasmussen LS; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
  • Winther SB; Department of Oncology, Odense University Hospital, Odense, Denmark.
  • Chen IM; Department of Oncology, Herlev-Gentofte University Hospital, Copenhagen, Denmark.
  • Weber B; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Ventzel L; Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark.
  • Liposits G; Department of Oncology, Gødstrup Hospital, Herning, Denmark.
  • Johansen JS; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Detlefsen S; Department of Pathology, Odense University Hospital, and Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
  • Egendal I; Center for Clinical Data Science (CLINDA), and Clinical Cancer Research Center, Aalborg University and, Aalborg University Hospital, Aalborg, Denmark.
  • Shim S; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Christensen S; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
  • Pfeiffer P; Department of Oncology, Odense University Hospital, and Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
  • Ladekarl M; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. morten.ladekarl@rn.dk.
BMC Cancer ; 23(1): 552, 2023 Jun 16.
Article em En | MEDLINE | ID: mdl-37328835
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Gencitabina Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Gencitabina Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article